Facebook
Twitter
LinkedIn
Forward
2025 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer)
Overview
The Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) is a multidisciplinary conference that brings together clinicians, scientists, researchers, and pharmaceutical industry experts in the field of oncology to provide and gain insight into recent advances in cancer science and medicine. The primary aim of the conference is to discuss recent advancements, challenges, and future directions in the areas of novel therapeutic agents and drug discovery, clinical trial design, molecular profiling, and precision oncology. STOP Cancer will highlight the latest in early phase research and interpretation and application of precision medicine.
Designation | Advance (Ends August 26, 2025 at 11:59 p.m. Pacific time) | Standard (Begins August 27, 2025 at 12:00 a.m. Pacific time) |
| MD, DO, PhD | $490 | $590 |
Allied Health (NP, PA, RN, PharmD, Fellows, Residents, Retired) | $275 | $375 |
| Industry** | $790 | $890 |
**Defined as anyone employed by a drug, device, or diagnostic company. We allow Industry Professionals to register for our conferences unless you are employed in a sales role with your company. Please note that we will accept a limited number of Industry Professionals (excluding sales) to each conference.
Refunds of 50% of the registration fee will be provided if you cancel up to 30 days before the Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP CANCER) commences. There are no refunds for cancellations within the 30-day window of the start of the event. To request a refund, please email [email protected]
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Pacific Standard Time Zone
Thursday, September 25, 2025 | |
| 11:00am | Pre-Conference Activity |
| 5:00pm | Pre-Conference Registration Opens |
| 6:00pm | Industry Sponsored Dinner |
Friday, September 26, 2025 | |
| 7:00am | Check-in and Breakfast in Exhibit Hall |
| 8:00am | Horizon CME App Overview and CE Housekeeping |
| 8:10am | Welcome, Introductions, & CE Housekeeping |
| 8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: TBA » TBA |
| 9:15am | Break | Refreshments in Exhibit Hall |
| Block One: Small Molecules and Targeted Therapy | |
| 9:40am | (02) Emerging Role of KAT6 Inhibitors in Cancer » Patricia LoRusso, DO - Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics Yale Cancer Center |
| 10:00am | (03) New Drugs in Lymphoma or subsets of Sarcomas Products from the clinical side / substitute products for MTAP + Bispecifics » TBA |
| 10:20am | (04) Targeting Death Receptors » TBA |
| 10:40am | (05) Q+A Panel and Discussion: Block One » Faculty from Sessions 02 - 04 |
| 11:00am | Gather for Lunch |
| 11:10am | Lunch |
| 11:55am | Dessert - Refreshments in Exhibit Hall |
| Block Two: Emerging Immunotherapeutic Platforms | |
| 12:10pm | (06) Emerging Role of Peptides and NeoAntigen Vaccines » Keith Knutson, PhD - Immunologist Mayo Clinic |
| 12:30pm | (07) Cell Therapy for Solid Tumors » Elena Garralda, MD - Medical Oncologist, Director, Early Drug Development Unit, Co-Director of VHIO’s Clinical Research Program Director of the Phase I Unit, Vall d’Hebron Institute of Oncology, NEXT Oncology |
| 12:50pm | (08) Q+A Panel and Discussion: Block Two » Faculty for Sessions 06 - 07 |
| 1:10pm | Message from the Cancer Charities |
| 1:25pm | Break - Trivia for Charity in the Exhibit Hall |
| Block Three: Recent Precision Medicine Advances in Hematology/Oncology | |
| 1:45pm | (09) Lung Cancers » Mihaela Aldea, MD, PhD - Assistant Professor, International Center of Thoracic Cancers, Paris Saclay University Medical Oncologist Gustave Roussy |
| 2:05pm | (10) Breast Cancers » TBA |
| 2:25pm | (11) GI Cancers » Mitesh Borad, MD - Professor of Medicine Mayo Clinic College of Medicine and Science |
| 2:45pm | (12) Acute Leukemia or MDS MPNS » Eytan Stein, MD - Hematologist-Oncologist Director, Drug Development in Leukemia Memorial Sloan Kettering Cancer Center |
| 3:05pm | (13) Q+A Panel and Discussion: Block Three » Faculty from Sessions 09 - 12 |
| Block Four: Clinical Advances in RAS Targeting | |
| 3:25pm | (14) RAS ON Inhibitors » Shubham Pant, MD, MBBS - Professor, Department of Gastrointestinal (GI) Medical Oncology The University of Texas MD Anderson Cancer Center |
| 3:45pm | (15) RAS Protacs and Molecular Glues » Anthony W. Tolcher, MD, FRCPC - Medical Oncologist, CEO and Founder of NEXT Oncology Texas Oncology-San Antonio Babcock Next Oncology |
| 4:05pm | (16) RAS Enzymatic Inhibitors » TBA |
| 4:25pm | (17) Q+A Panel and Discussion: Block Four » Faculty from Sessions 14 - 16 |
| 4:45pm | Networking Reception - Exhibit Hall |
Saturday, September 27, 2025 | |
| 7:00am | Check-in |
| 7:55am | Horizon CME App Overview and CE Housekeeping |
| 8:00am | Welcome and Introductions |
| Block Five: Biomarker Methodology in Cancer | |
| 8:10am | (18) ctDNA Applications in Management of Advanced Disease Patients on Investigational Agents - heme perspective - Myeloma - MRD end point » TBA |
| 8:30am | Gather for Breakfast |
| 8:35am | Breakfast Symposium sponsored by TBA » TBA |
| 9:20am | Transition Break |
| 9:25am | (19) AI as a Predictive Model in Drug Targets » Irbaz B. Riaz, MBBS, PhD - Oncologist Mayo Clinic |
| 9:45am | (20) How Biomarkers are used to Guide Treatment with Bispecifics » TBA |
| 10:05am | (21) Digital Molecular Pathology » Kurt Schalper, MD, PhD - Associate Professor of Pathology, Director, Translational Immuno-oncology Laboratory Yale School of Medicine |
| 10:25am | (22) Q+A Panel and Discussion: Block Five » Faculty from Sessions 18 - 21 |
| 10:45am | Break - Refreshments in the Exhibit Hall |
| 11:05am | Poster Session |
| Block Six: Clinical Trial Methodology | |
| 11:50am | (23) Strategies for Patient Recruitment » Kelly Bolton, MD, PhD - Assistant Professor Washington University |
| 12:10pm | (24) Novel Endpoints for Therapeutic Response in Early Phase Trials » Jordi Rodon Ahnert, MD, PhD - Associate Professor, Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center |
| 12:30pm | (25) The Evolution of Agnostic Drug Approval: Where Are We Now? » Vivek Subbiah, MD - Chief, Early-Phase Drug Development, Sarah Cannon Research Institute |
| 12:50pm | (26) Role of Patient Advocacy in Early Phase Trials » Melinda Bachini - Chief Patient Officer Cholangiocarcinoma Foundation |
| 1:10pm | (27) Q+A Panel and Discussion: Block Six » Faculty from Sessions 23 - 26 |
| 1:30pm | Gather for Lunch |
| 1:35pm |
Buffet Lunch & Non-CME/CE Presentation Sponsored by TBA » TBA |
| 2:20pm | Dessert Break in Exhibit Hall |
| Block Seven: RAS Targeting and Other Drugs Targeting the Cell Surface | |
| 2:35pm | (28) Radiopharmaceuticals in Drug Development » TBA |
| 2:55pm | (29) Innovations in HER2 Targeted Therapy » Alison Schram, MD - Gynecologic Medical Oncologist, Early Drug Development Specialist Memorial Sloan Kettering Cancer Center |
| 3:15pm | (30) Pre-Clinical Considerations in ADC Development » Daruka Mahadevan, MD, PhD - Professor of Medicine, Tenured, Chief, Division of Hematology/Medical Oncology, AT&T President’s Distinguished University Chair, Director, Institute for Drug Development, Associate Director Clinical Research Mays Cancer Center, University of Texas Health |
| 3:35pm | (32) Clinical Advances in ADC Development and Novel Payloads » Toshio Shimizu, MD, PhD - Professor, Department of New Experimental Therapeutics Director, International Cancer New Drug Development Center Kansai Medical University Hospital Director of Clinical Research and CEO, NEXT Oncology JAPAN |
| 3:55pm | Break - Refreshments in the Exhibit Hall |
| 4:15pm | (32) Novel Combination Approaches for ADC Therapeutics + Novel ADC Targets in Solid Tumors » TBA |
| 4:35pm | (33) Toxicity Management Considerations with Current ADC Landscape - combine with payloads » Antonio Giordano, MD, PhD - Medical Oncologist, Clinical Investigator Dana-Farber Cancer Institute |
| 4:55pm | (34) Q+A Panel and Discussion: Block Seven » Faculty from Sessions 28 - 33 |
| 5:15pm | Closing Comments |
We want to ensure that your time at the 2025 Summit for Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) conference is convenient and memorable. Staying at our host hotel provides a hassle-free experience and puts you at the heart of the activity surrounding the conference.
Overnight Accommodations:
Booking Deadline: August 26, 2025
Click here to book your room today!
Room rate: Thursday: $329 | Friday & Saturday: $379
Parking: $45 Overnight Parking, Daily $25
Disclaimer:
All reservations must be booked using the link above before the closing date listed. Overnight accommodation, parking, and resort fees will revert back to standard hotel pricing outside of the dates above. A set number of rooms have been blocked off for the discounted pricing. If all of those rooms have already been booked, discounted pricing may not be available for additional rooms or accommodations.
Available Credit
- 9.25 ABIM Medical KnowledgeHorizon CME, Inc. designates this activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 9.25 ACPE PharmacyThe Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 9.25 credit by the Washington State Pharmacy Association.
This activity is approved for up to 9.25 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Thu, 09/25/2025 - 8:30am-Sat, 09/27/2025 - 4:10pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 60 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171 - 9.25 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 9.25 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 9.25 credit.
- 3.50 PharmacologyThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 3.50 credit.